Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Novavax developing vaccine that targets new COVID-19 variant

11/26/2021 | 06:04pm EST
FILE PHOTO: FILE PHOTO: A woman holds a small bottle labeled with a

(Reuters) -Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.

The company's COVID-19 shot contains an actual version of the virus' spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.

"The initial work will take a few weeks," a company spokesperson said. Shares of the company closed up nearly 9% on Friday.

Novavax's vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines.

The company has said it is on track to file for U.S. approval by the end of the year. It has also filed for approvals with the European Medicines Agency as well as in Canada.

Other vaccine developers, including Germany's BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organisation.

Inovio Pharmaceuticals Inc said it had begun testing its vaccine candidate, INO-4800, to evaluate its effectiveness against the new variant. The company expects the testing to take about two weeks.

Inovio also said it was simultaneously designing a new vaccine candidate that specifically targeted Omicron.

"Best case scenario, INO-4800 ... will be completely resilient against omicron, but if that's not the case then we will have a newly designed vaccine ready to go if need be," said Kate Broderick, senior vice president of Inovio's R&D division.

Earlier this month, Inovio resumed a late-stage trial of its vaccine in the United States after 14 months on clinical hold.

(Reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Anil D'Silva)

By Manojna Maddipatla and Mrinalika Roy

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -3.44% 196 Delayed Quote.-23.97%
DOW JONES AFRICA TITANS 50 INDEX -0.76% 555.77 Delayed Quote.3.56%
DOW JONES SOUTH AFRICA(ZAR) -0.88% 2038.57 Delayed Quote.3.61%
INOVIO PHARMACEUTICALS, INC. 3.04% 4.75 Delayed Quote.-4.81%
NOVAVAX, INC. -1.39% 110.82 Delayed Quote.-22.54%
S&P AFRICA 40 INDEX -0.52% 182.84 Delayed Quote.4.35%
Latest news "Economy & Forex"
05:58aBeijing tightens rules for entering city after Omicron case
05:48aThailand reports first death from Omicron coronavirus variant
05:48aPrivate equity firm ardian to buy italian drug firm biofarma group for 1.1 bln euros - sources
05:48aBuyout fund Ardian makes $1.2 bln swoop on Italy's Biofarma Group - sources
05:45aSpanish Civil War bomb found after man recalls childhood attack
05:27aPhilippines says 'indispensable' Suu Kyi must be involved in Myanmar peace process
05:12aUK PM Johnson must address culture that led to lockdown parties - Conservative chairman
05:04aUK PM Johnson broke the law and lied about it - opposition leader Starmer
04:52aSomali government spokesman wounded by suicide bomb blast -police, state media
04:51aSignificant tsunami damage feared in Tonga, communications still cut
Latest news "Economy & Forex"